818 related articles for article (PubMed ID: 21441910)
1. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK.
Brennan DF; Dar AC; Hertz NT; Chao WC; Burlingame AL; Shokat KM; Barford D
Nature; 2011 Apr; 472(7343):366-9. PubMed ID: 21441910
[TBL] [Abstract][Full Text] [Related]
2. MEK drives BRAF activation through allosteric control of KSR proteins.
Lavoie H; Sahmi M; Maisonneuve P; Marullo SA; Thevakumaran N; Jin T; Kurinov I; Sicheri F; Therrien M
Nature; 2018 Feb; 554(7693):549-553. PubMed ID: 29433126
[TBL] [Abstract][Full Text] [Related]
3. A dimerization-dependent mechanism drives RAF catalytic activation.
Rajakulendran T; Sahmi M; Lefrançois M; Sicheri F; Therrien M
Nature; 2009 Sep; 461(7263):542-5. PubMed ID: 19727074
[TBL] [Abstract][Full Text] [Related]
4. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
5. Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling.
Haling JR; Sudhamsu J; Yen I; Sideris S; Sandoval W; Phung W; Bravo BJ; Giannetti AM; Peck A; Masselot A; Morales T; Smith D; Brandhuber BJ; Hymowitz SG; Malek S
Cancer Cell; 2014 Sep; 26(3):402-413. PubMed ID: 25155755
[TBL] [Abstract][Full Text] [Related]
6. Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico.
Fleischmann J; Feichtner A; DeFalco L; Kugler V; Schwaighofer S; Huber RG; Stefan E
Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33808483
[TBL] [Abstract][Full Text] [Related]
7. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.
Dhawan NS; Scopton AP; Dar AC
Nature; 2016 Sep; 537(7618):112-116. PubMed ID: 27556948
[TBL] [Abstract][Full Text] [Related]
8. The mechanism of activation of MEK1 by B-Raf and KSR1.
Maloney RC; Zhang M; Liu Y; Jang H; Nussinov R
Cell Mol Life Sci; 2022 May; 79(5):281. PubMed ID: 35508574
[TBL] [Abstract][Full Text] [Related]
9. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.
Ishii N; Harada N; Joseph EW; Ohara K; Miura T; Sakamoto H; Matsuda Y; Tomii Y; Tachibana-Kondo Y; Iikura H; Aoki T; Shimma N; Arisawa M; Sowa Y; Poulikakos PI; Rosen N; Aoki Y; Sakai T
Cancer Res; 2013 Jul; 73(13):4050-4060. PubMed ID: 23667175
[TBL] [Abstract][Full Text] [Related]
10. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
11. MEK1/2 dual-specificity protein kinases: structure and regulation.
Roskoski R
Biochem Biophys Res Commun; 2012 Jan; 417(1):5-10. PubMed ID: 22177953
[TBL] [Abstract][Full Text] [Related]
12. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
13. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
14. Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization.
Liau NPD; Wendorff TJ; Quinn JG; Steffek M; Phung W; Liu P; Tang J; Irudayanathan FJ; Izadi S; Shaw AS; Malek S; Hymowitz SG; Sudhamsu J
Nat Struct Mol Biol; 2020 Feb; 27(2):134-141. PubMed ID: 31988522
[TBL] [Abstract][Full Text] [Related]
15. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
[TBL] [Abstract][Full Text] [Related]
16. The CNK-HYP scaffolding complex promotes RAF activation by enhancing KSR-MEK interaction.
Maisonneuve P; Sahmi M; Bergeron-Labrecque F; Ma XI; Queguiner J; Arseneault G; Lefrançois M; Kurinov I; Fronzes R; Sicheri F; Therrien M
Nat Struct Mol Biol; 2024 Feb; ():. PubMed ID: 38388830
[TBL] [Abstract][Full Text] [Related]
17. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
18. MEK1 activation by PAK: a novel mechanism.
Park ER; Eblen ST; Catling AD
Cell Signal; 2007 Jul; 19(7):1488-96. PubMed ID: 17314031
[TBL] [Abstract][Full Text] [Related]
19. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.
Hu J; Yu H; Kornev AP; Zhao J; Filbert EL; Taylor SS; Shaw AS
Proc Natl Acad Sci U S A; 2011 Apr; 108(15):6067-72. PubMed ID: 21441104
[TBL] [Abstract][Full Text] [Related]
20. Complexity in KSR function revealed by Raf inhibitor and KSR structure studies.
McKay MM; Freeman AK; Morrison DK
Small GTPases; 2011 Sep; 2(5):276-281. PubMed ID: 22292131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
